Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Tavneos on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Switzerland
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Tavneos (avacopan) is an oral complement C5a receptor antagonist approved for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis — specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) — used in combination with standard therapy including glucocorticoids.
Tavneos blocks the C5a receptor, part of the complement system that drives inflammation and tissue damage in ANCA-associated vasculitis. By blocking this pathway, Tavneos helps reduce inflammatory activity, allowing for reduced reliance on high-dose glucocorticoids over time.
Tavneos is intended for adults with severe active GPA or MPA as an add-on to standard therapy, not as a standalone treatment, and is typically used to help reduce glucocorticoid exposure during vasculitis management.
The recommended dose of Tavneos is 30 mg (three 10 mg capsules) taken orally twice daily with food.
Tavneos does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Serious hepatotoxicity, including cases of vanishing bile duct syndrome, has been reported. Liver function should be monitored before and periodically during treatment.
Serious hypersensitivity reactions, including angioedema, have been reported. Tavneos should be discontinued if a serious reaction occurs.
Reactivation of hepatitis B virus has occurred in some patients. Screening for hepatitis B prior to treatment is recommended where appropriate.
Tavneos may increase susceptibility to infections, particularly when used alongside other immunosuppressive therapies. Patients should be monitored for signs of infection throughout treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Tavneos is manufactured and marketed by Vifor Fresenius Medical Care Renal Pharma for European markets. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating rheumatologist or nephrologist confirming ANCA-associated vasculitis diagnosis. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an approved therapy for severe active ANCA-associated vasculitis, Tavneos is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Tavneos directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Tavneos should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Tavneos through NPP's regulated import pathway, with rheumatology and nephrology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support rheumatology and nephrology care coordination and documentation for Tavneos access.
Delhi's major hospitals assist patients with prescription support and documentation for Tavneos.
Bangalore's specialist network offers access coordination for eligible vasculitis patients seeking Tavneos.
Chennai-based rheumatology specialists coordinate Tavneos access alongside comprehensive vasculitis care.
Hyderabad's care institutions support patients pursuing Tavneos therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Tavneos.
Pune-based specialists assist with prescription support and Tavneos treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Tavneos.
Kochi's specialist units assist patients with the documentation needed for Tavneos access.
Chandigarh's care centers support Tavneos treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Tavneos access process.
Lucknow-based centers assist patients pursuing Tavneos therapy.
Bhubaneswar's institutions support access to Tavneos for eligible patients.
Guwahati's specialists help coordinate Tavneos access for patients across the Northeast.
Patients in other cities across India can also access Tavneos through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.jpg)
